23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
23:03 , Nov 2, 2018 |  BioCentury  |  Finance

Innovent’s Hong Kong spark

A strong performance out of the gate for Innovent Biologics Inc. (HKSE:1801) reflects investor confidence in the company’s pipeline regardless of market conditions. The biologics company raised HK$3.3 billion ($421 million) in an IPO priced...
21:47 , Nov 2, 2018 |  BC Extra  |  Financial News

Trump, Xi talks boost Chinese biopharma stocks

Chinese biopharma stocks rose on Friday following trade discussions between President Donald Trump and Chinese President Xi Jinping. On Friday, double-digits gainers included Innovent Biologics Inc. (HKSE:1801), which added HK$1.76 (10%) to HK$18.72; WuXi Biologics...
20:01 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Innovent shares rise in first day of Hong Kong trading

Innovent Biologics Inc. (HKSE:1801) gained HK$2.60 (19%) to HK$16.58 in its first day of trading Oct. 31, delivering the strongest first-day performance yet for a biotech listing on the Hong Kong stock exchange's new biotech...
14:19 , Oct 31, 2018 |  BC Extra  |  Financial News

Innovent shares rise in first day of Hong Kong trading

Innovent Biologics Inc. (HKSE:1801) gained HK$2.60 (19%) to HK$16.58 in its first day of trading Wednesday, delivering the strongest first-day performance yet for a biotech listing on the Hong Kong stock exchange's new biotech chapter....
17:41 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange on Oct. 24, raising HK$3.3 billion ($421 million). Innovent sold 236.4 million shares at HK$13.98, near the top...
21:05 , Oct 24, 2018 |  BC Extra  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange, raising HK$3.3 billion ($421 million), according to a source close to the deal who asked not to be...
19:32 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Reports say Innovent seeking $422M IPO in Hong Kong

Innovent Biologics Inc. (Suzhou, China) did not respond to inquiries regarding reports that the company is seeking to raise $422 million in an IPO on the Hong Kong stock exchange, which would value the company...
17:29 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

Innovent Biologics Inc. (Suzhou, China) said anti-PD-1 antibody sintilimab (IBI308) led to an objective response rate (ORR) of 22.7% in 22 evaluable patients with neuroendocrine tumors (NETs) who failed standard therapy in a Chinese Phase...
21:57 , Sep 21, 2018 |  BC Extra  |  Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...